Indonesia Clinical Nutrition for Chronic Kidney Diseases Market Analysis

Indonesia Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

Indonesia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $9.40 Mn in 2023 and is predicted to grow at a CAGR of 6.03% from 2023 to 2030, to $14.20 Mn by 2030. 

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. The main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

The prevalence of chronic kidney disease (CKD) in Indonesia is reported to be around 0.5% according to the National Basic Health Survey. Another study found a slightly lower prevalence of 0.38%, with regional variations showing the highest prevalence in North Kalimantan at 0.64% and the lowest in West Sulawesi at 0.18%. The market therefore is driven by significant factors like the rising prevalence of CKD, advancements in healthcare infrastructure, and technological innovations. However, the high cost of treatment, regulatory hurdles, and scarcity of qualified dietitians restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

​

Market Dynamics

Market Growth Drivers

Rising Prevalence of CKD: Indonesia faces a significant burden of CKD due to rising rates of diabetes, hypertension, and other non-communicable diseases. The increasing prevalence necessitates specialized clinical nutrition solutions to manage the condition effectively. According to the 2018 Riskesdas survey, CKD affects approximately 0.38% of the Indonesian population, underscoring the demand for targeted healthcare interventions.

Advancements in Healthcare Infrastructure: Improvements in healthcare infrastructure and access to specialized care facilities contribute to the growth of the clinical nutrition market. Expanded healthcare services enable more patients to receive timely diagnosis, treatment, and nutritional support tailored to their CKD stage and individual needs.

Technological Innovations: Advances in medical research and technology drive innovation in clinical nutrition for CKD. New formulations of nutritional products, along with telemedicine and digital health solutions, enhance accessibility to nutrition counseling and monitoring for CKD patients across South Africa.

Market Restraints

High Cost of Treatment: CKD management involves considerable healthcare expenses, including medications, dialysis, and specialized clinical nutrition products. The high cost of these treatments can be a significant barrier for patients, particularly those without adequate health insurance coverage or financial resources.

Regulatory Hurdles: Regulatory complexities and stringent approval processes for clinical nutrition products may delay market entry and limit product availability. Compliance with local health authority requirements adds to operational challenges for manufacturers and distributors.

Scarcity of Qualified Dietitians: There is a shortage of dietitians in Indonesia with expertise in CKD nutrition, which restricts patients' access to specialized nutritional guidance and tailored dietary management plans.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for CKD-specific clinical nutrition in Indonesia is primarily overseen by Badan Pengawas Obat dan Makanan (BPOM) and the Ministry of Health (Kemenkes). BPOM regulates the safety, efficacy, and quality of all food and drug products, including specialized nutritional products for CKD management, requiring manufacturers to obtain approval before marketing their products. The Ministry of Health sets broader healthcare guidelines and regulations, defining the scope of practice for dietitians and potentially issuing recommendations for CKD nutritional therapy. Key regulations include BPOM's rules for "makanan khusus untuk keperluan medis" (special foods for medical purposes) and relevant permits issued by the Ministry of Health.

Reimbursement for CKD-specific clinical nutrition in Indonesia is managed under the national health insurance program, JKN, which covers a broad range of healthcare services. However, the extent of coverage for CKD nutritional interventions varies based on the patient's condition, specific products, and the treatment facility. When JKN coverage is limited, patients may face significant out-of-pocket expenses for necessary CKD nutritional products and dietitian consultations, posing a financial burden.

Competitive Landscape

Key Players

Here are some of the major key players in the Indonesia Clinical Nutrition for Chronic Kidney Diseases Market

• Abbott Nutrition
• Pfizer Inc.
• Bayer AG
• Nestlé Health Science
• Otsuka Pharmaceutical
• Mead Johnson & Company, LLC
• Danone S.A.
• Victus, Inc.
• B. Braun Melsungen AG
• Fresenius Kabi AG